QuickView: Building better biologicals
Six monoclonal antibody candidates, developed using Abzena’s humanising technology, are now in Phase I and II clinical studies with partners. Most notable is Gilead’s simtuzumab (for cancer/liver disease), a potential blockbuster on which Abzena would receive low single-digit royalties. This points to significant potential value creation, while the existing biological engineering services provides steady revenues (£2.4m in H115). With a healthy cash balance following a £20m IPO, Abzena is well positioned to generate fresh licensing and services business, on greater economic terms.Abzena is providing a range of complementary services and technologies for the selection, development and manufacture of biopharmaceuticals.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.